SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer
Executive Summary
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
You may also be interested in...
Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups
US FDA labeling details the differences in performance of neratinib in adjuvant breast cancer by subgroup, as well as results relative to the timing of Roche's Herceptin, but the drug's indication covers all.
MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo
MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.
Need a specific report? 1000+ reports available
Buy Reports